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Abstract
Background: Postoperative assessment of indications for cancer directed surgical procedures
frequently differs from preoperative plans.
Methods: Specifically defined preoperative indications and postoperative results were followed
prospectively over 48 months in a single surgeon academic practice, and relationships to
postoperative outcomes evaluated.
Results: Operations were performed on 406 patients with a median age of 61 (range: 18–90).
Major operations (n = 303, 75%) involved 270 abdominal resections including pancreatectomies
(37%), liver resections (23%), gastrectomies (19%), and others (21%). Preoperative curative (70%),
diagnostic (38%), palliative (12%), access (9%), and non-cancer related therapy (21%) goals were in
part combined in 176 patients (43%). Postoperative assessment differed from preoperative goals in
118 patients (29%). Predominant reasons were proof of benign disease (n = 35), incomplete
resection (R1 or R2, n = 23), unresectability by laparoscopy (n = 21) or laparotomy (n = 21), or
others (n = 18). Potential preoperative cure or palliation goals were not achieved in 37% or 15%
of cases, respectively. Circumstances of changed treatment intent were specific for disease site.
Conclusion: Preoperative therapeutic intent frequently differs from postoperative assessments in
gastrointestinal cancer, based on shortcomings in diagnosis or therapy. Formulations of precise
operative indications are recommended to optimize individual outcomes and avoid unnecessary or
ineffective procedures.
Background
Solid tumors provide most of the indications for operative
therapy within surgical oncology. The majority of solid
tumors reflect a malignant process, most of which in turn
require complete local control through resection in order
to achieve a successful long-term treatment result.
Although multimodality therapy has improved treatment
options and outcomes for many cancers, successful cures
are rarely achieved through nonoperative modalities
alone. Chemoradiation approaches to anal cancer [1] or
systemic therapy for testicular cancer represent some
exceptions to this rule [2]. As a result of this historically
developed factum, indications to perform operative ther-
apy are frequently assumed just due to the mere presence
of apparently localized, "resectable" disease. Definitions
of patient "operability" (e.g. additional comorbidity or
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ation) and tumor "resectability" (complete control of
macroscopically identifiable disease through resection)
vary widely, dependent of the quality of preoperative
imaging and the individual surgeon's judgment. This is
likely reflected in the fact that for many complex cancer
operations, surgeon experience and volume have been
found to have prognostic impact [3-7]. Many surgeons
tend to resort to personal experience and subjective crite-
ria in the process of deciding in favor of or against an
operation. Goals for such therapy tend to not infrequently
remain unstated, be imprecise, or become bundled such
as in cases of complex tumor presentations in patients
with associated symptoms, for instance due to gastrointes-
tinal cancer. If a resection necessary to allow for a curative
result cannot be performed, lesser extent procedures such
as bypass operations are still commonly performed in
order to prevent or ameliorate problems related to the per-
sisting tumor [8], even if nonoperative palliative measures
exist. Additionally, goals to completely eradicate the
tumor mass and to treat related symptoms at the same
time frequently have to be combined. However, postoper-
ative outcomes frequently differ from stated operative
goals, as true cures are sparse [9-11], and as for palliative
procedures survival may be short [12], with symptom
control frequently being poor [13,14] or short lived [15].
Many clinical series underreport problems related to
changes in operative extent or intent, and focus instead on
patient cohorts treated uniformly by resection or bypass
procedures. However, one measure for treatment success
of cancer operations should be the frequency of reaching
preoperatively defined therapeutic goals, which is directly
dependent on the precision with which these goals are
formulated. The current study reflects an attempt to define
specific therapeutic goals preoperatively, measure the
ability of achieving these goals, and study some mecha-
nisms that determine success or failure in this context.
Patients and methods
The analysis is based on preoperative decisions and post-
operative findings of all patients undergoing an operative
procedure by a single surgeon in an academic, tertiary care
cancer center setting with a clinical focus on gastrointesti-
nal cancer. Not all patients had a specified cancer-related
operative indication. Specifically defined preoperative
indications and postoperative results were followed pro-
spectively over 48 months from January 2002 until
December 2005. Surgical treatment intent was classified
based on five predefined categories of curative, palliative,
diagnostic, access, and nonmalignant therapeutic goals.
Operations were defined as of "curative" intent when
designed to completely remove proven or suspected
malignant disease for lasting freedom of cancer or a signif-
icant survival benefit. "Palliative" procedures had the
intent to control specific symptoms caused directly by a
malignant process that itself was not amenable to cure,
such as malignant bowel obstruction due to peritoneal
carcinomatosis. "Diagnostic" operations were to clarify an
uncertain or unproven diagnosis through removal of tis-
sue, or an unclear therapy-relevant disease extent through
intraoperative imaging methods. "Access" procedures
were to provide operative vascular, enteric, airway, or
body cavity access for foreign devices helpful in a patient's
management, such as intravenous or intraperitoneal
implantable chemotherapy port placement. An operation
was deemed "therapeutic" when indicated to treat a
patient's nonneoplastic condition irrespective of the pres-
ence of a cancer diagnosis, such as incisional hernia repair
or cholecystectomy for cholecystitis. Based on these defi-
nitions, multiple intent group assignments were specifi-
cally possible; for instance, the dual assignment "curative/
palliative" was given, when preoperative clinical staging
did not reveal extraregional metastatic disease, but cancer-
related symptoms would justify an operation even when
metastatic disease was identified intraoperatively. For
elective, curative intent procedures, all patients had
undergone state-of-the-art crossectional imaging by either
computed tomography (favored for gastrointestinal and
pancreatic malignancies) or magnetic resonance imaging
(favored for hepatobiliary and soft tissue tumors); preop-
erative biopsies or endoscopic ultrasound examinations
were utilized selectively to clarify questions important in
the decision making process for operative therapy. For this
"state-of-the-art" imaging, scans obtained prior to the
patient's initial presentation were acceptable, as long as
the defined objectives were felt to be sufficiently accom-
plished. These included absence of extraregional meta-
static disease, and sufficient evidence for loco-regional
resectability, primarily in relation to major vascular struc-
tures. Loco-regional criteria were thus organ- or site-spe-
cific. For instance, for pancreatic lesions, multiphase fine-
cut helical scans were expected to delineate tumor extent,
and prove freedom of superior mesenteric, vascular and
portal vasculature; for hepatobiliary lesions, multiphase,
fine-cut scans were expected to show intrahepatic disease
extent, as well as lack of involvement of vascular structures
within the hepatoduodenal ligament or at the hepatic
veins. If these criteria were not answerable based on out-
side scans, specific scans were ordered based on disease-
site protocol criteria. Clinical diagnosis and stage, as well
as preoperative treatment intent were charted preopera-
tively. Diagnostic laparoscopy was routinely performed at
the beginning of operations with curative intent for upper
gastrointestinal, pancreatic, periampullary, and biliary
cancers; when performed in this routine fashion, this
component was not charted as diagnostic procedure.
Operative findings and the procedure performed were
documented postoperatively, in addition to pathology
findings and postoperative outcomes. All operative cases
were classified as major or minor. Major operationsPage 2 of 9
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tion, extended lymphadenectomy, or any procedure
requiring anastomotic reconstruction; in addition, emer-
gency procedures such as cholecystectomy for gangrenous
cholecystitis in a neutropenic patient were classified simi-
larly. Minor cases included resections of smaller scope
(e.g. elective cholecystectomy), nonresective/nonanasto-
motic procedures, extrinsic diversions, access procedures,
or biopsies. Postoperative mortality was based on lethal
events occurring within 30 days after operation or during
the postoperative in-hospital stay if longer than 30 days.
Postoperative morbidity included any untoward events
deviating from normal recovery and requiring diagnostic
or therapeutic intervention; events requiring intensive
care, reoperations, or interventional radiological manage-
ment were considered major complications. Postopera-
tive treatment intent reassessment was carried out for each
preoperative treatment goal, and successful as well as
unsuccessful intent realization based on intraoperative
findings or pathology results was documented. Relation-
ships between preoperative and postoperative treatment
goals, and group comparison of nominal variables were
evaluated via chi square contingency analysis or Fisher's
exact test, as appropriate. Variables predicting the failure
to achieve a preoperative treatment intent category were
examined through logistic regression analyses, employing
a stepwise backward methodology. Covariates entered
into this model were all demographic and clinicopatho-
logic variables, organ site information, and all preopera-
tive intent categories (such as curative yes/no, etc.). For
the group comparison of postoperative length of stay, a
nonparametric product-limit method with Peto-Peto-Wil-
coxon test was chosen as described earlier [16]. Postoper-
ative deaths were excluded from length of stay analysis.
Group differences were assumed significant at p < 0.05.
All analyses were performed with StatView 5.0.1 software
for Macintosh computers (SAS Institute Inc., Cary, NC).
Results
Patient demographics and operative treatment
During the defined time interval, operations were per-
formed on 406 patients. There were 198 males (49%) and
208 females (51%), with a median age of 61 (range: 18–
90). Three hundred and two patients had a final diagnosis
of cancer (74%), of whom 73% underwent a major oper-
ation. The proportion of major operations in patients
with a benign diagnosis (n = 104, 26%) was 80%. Major
operations were altogether performed in 303 individuals
(75%) and predominantly involved transabdominal
resections (n = 270). The distribution of resections among
organ sites included pancreatectomies (37%), liver resec-
tions (23%), gastrectomies (19%), and others such as
esophagectomies, intestinal or soft tissue resections
(together 21%). The ratio of malignant versus benign
diagnoses undergoing major resection did not show sig-
nificant differences among various organ sites; 73% of
pancreatectomies, 79% of hepatobiliary resections, 78%
of gastrectomies, and 69% of other organ resections were
performed for cancer. Thirty-four operations were per-
formed as emergencies (8.4%); of all cancer-directed pro-
cedures, 6% were emergencies, compared to 15.4% of
operations for a nonmalignant process (p = 0.006). The
utilization of preoperative diagnostic studies and laparos-
copy varied by organ site (Table 1).
Preoperative treatment intent
The preoperatively defined treatment plan listed curative
goals in 70%, diagnostic in 38%, palliative in 12%, access-
related in 9%, and non-cancer related therapy goals for
21% of all patients. Various treatment goals were com-
bined in 176 individuals (43%).
Procedures in patients with preoperative curative goals
differed from those without curative goals, with regard to
resections (82% vs. 30%), bypasses or diversions (3% vs.
Table 1: Utilization for standard diagnostic procedures, by intraabdominal organ site 
Organ site CT MRI EUS Laparoscopy
Esophagus (n = 10) 100 0 40 60
Stomach (n = 72) 93 10 28 56
Small bowel (n = 18) 83 6 6 33
Colon (n = 17) 88 12 0 6
Rectum (n = 19) 95 21 44 11
Liver (n = 84) 83 83 2 15
Bile ducts (n = 47) 96 43 13 53
Pancreas (n = 125) 95 32 40 76
Retroperitoneum (n = 12) 100 67 8 17
Soft tissues (n = 10) 80 40 10 10
Numbers reflect % (rounded) of patients within the disease group who had undergone the diagnostic test. The patient numbers within diagnostic 
sites do not add up to 406, since extraabdominal and hematologic diagnoses were excluded, and 75 patients carried combined diagnoses of different 
organ sites.Page 3 of 9
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Similarly, nineteen percent of patients with preoperative
palliation goals underwent a bypass procedure (versus 3%
of those without palliation needs), and 74% a resection
(versus 65% of those without palliation needs, p <
0.0001). Six percent of emergency operations still carried
curative plans, while 41% were performed in order to
achieve palliation. The highest frequencies of curative
indications were created for pancreatic (95%), esophageal
(90%), gastric (84%), small bowel (82%), retroperitoneal
(80%), and hepatobiliary (74%) diagnoses. Conversely,
palliative goals were most prevalent in patients with pel-
vic (45%), colon (44%), gynecologic (33%), gastric
(29%), and small bowel disorders (27%). Seventy-six per-
cent of access goals were carried out in minor procedures,
while 3% of major cases were to have an access procedure
component (p < 0.0001). Cancer was ultimately con-
firmed in 64% of patients with a planned diagnostic com-
ponent to the operation, while 33% of cancer patients
underwent an operation with a diagnostic goal (p =
0.0001). Treatment goals unrelated to the cancer were to
be addressed in 8% of patients at the same time of
attempting a curative operation.
Postoperative outcomes
The overall postoperative mortality for the entire cohort
was 4.7%, based on 19 lethal events after 406 operations.
Mortality figures did not differ significantly when com-
pared by diagnostic group or operative extent (Table 2).
However, the death rate after emergency operations
(11.4%) exceeded that after elective operations (4.0%, p =
0.04).
Postoperative complications were encountered in 98
patients (24%); fifty-three of these were classified as
major, representing 13% of all patients. Major complica-
tions were associated with major operative procedures,
but not related to diagnostic group (Table 2). Major com-
plications occurred in 19% of patients after pancreatec-
tomy, 15% after hepatectomy, 18% after gastrectomy, and
19% after other major resections (p = N.S.). Twenty four
percent of emergency operations led to a major complica-
tion, compared to 12% of nonemergent cases (p = 0.058).
The median postoperative length of stay was 8 days (range
1–100) after major operations, and 1 day after minor pro-
cedures (0–33; p < 0.0001). A cancer diagnosis did not
significantly influence the hospital stay (7 versus 6 days, p
= N.S.), but an emergency setting did, both for major (9
versus 8 days, p = 0.01) and minor (6 versus 0 days, p =
0.04) cases.
Postoperative reassessment of treatment intent
Postoperative assessment, based on intraoperative find-
ings and histopathological results, differed from preoper-
ative goals in 118 patients (29%). The majority of cases to
account for this difference were those of preoperative cur-
ative intent, but not classifiable as curative postopera-
tively (Figure 1). Potential preoperative cure goals were
not achieved in 37% of cases. Predominant reasons for
any postoperative intent change were proof of benign dis-
ease after a possible cancer had been assumed preopera-
tively (n = 35), incomplete resection (R1 or R2, n = 23),
unresectability by laparoscopy (n = 21) or laparotomy (n
= 21), or others (n = 18), as listed in detail in Figure 2.
Most "other" causes for curative intent changes could be
traced to uncertainty of diagnosis or disease extent; in
only two patients, intraoperative bleeding prevented the
completion of a curative procedure. Reasons for a change
of preoperative curative intent were strongly dependent
on the preoperative biopsy status, as listed in Table 3. All
of the 35 patients in the "benign disease proven" category
(i.e. postoperative pathology findings revealing a benign
process in a patient suspected to have cancer) still
required an operation for diagnostic clarification and
other therapeutic reasons (i.e. resection of a noninvasive
intraductal papillary mucinous neoplasms of pancreas).
While all 21 patients with a positive laparoscopy can be
considered appropriately treated, 13 of 23 patients with
R1/2 status (57%) and 16 of 21 patients found unresecta-
ble at open laparotomy could have been spared an open
operation under ideal circumstances, primarily if a proper
endoscopic ultrasound had been performed, if laparos-
copy had been performed, if a laparoscopy would not
have been false negative, or if the open operation was
merely conducted for a curative intent reason without pal-
liation needs. These 29 individuals comprise 7% of the
entire cohort, or 25% of 118 patients with postoperative
intent change; conversely, 75% of operations with intent
change were still justifiable.
Of 136 patients with a potential preoperative curative
intent who had been categorized preoperatively according
Table 2: Outcomes by diagnostic group and procedure extent
Total cohort Cancer Benign Major operation Minor operation
Major complications (%) 13 14 11 17* 1*
Mortality (%) 4.7 5.3 2.9 5.6 1.9
LOS, d (range) 7 (0–100) 7 (0–60) 6 (0–100) 8 (1–100)* 1 (0–33)*
• p < 0.0001 (Major versus minor operation)Page 4 of 9
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(68%) ultimately had a cancer confirmed. In these, the
ability to predict cancer followed a highly correlative pat-
tern: of 23 patients with a lower possibility for cancer (i.e.
cystic lesion of pancreas with wall abnormality), only one
was found to have invasive cancer (4%); 23 of 44 patients
(58%) with a likely cancer (i.e. solid mass), and 68 of 69
patients (99%) with preoperative biopsy proof were ulti-
mately confirmed to have a malignancy. The false positive
event was a patient with biopsy-proven gastric cancer who
was found to have complete resolution of endoscopic
abnormalities prior to his planned gastrectomy.
The frequency of unresectability findings (by metastases
and local extent) differed depending on the organ to be
resected, limiting planned biliary and gastroesophageal
resections most often as listed in Table 4. Multivariate
analysis variables associated with the failure to perform a
curative resection, based on the confirmation of unre-
sectability or R1/2 resection, are listed in Table 5. They
represent certain organ sites with high metastasis poten-
tial, and complex clinical presentation with combined
palliation and cure intents. Some circumstances of
changed treatment intent were specific for disease site; the
following p values represent comparisons to other disease
sites. Among pancreas cases, 40% of changes were non-
cancerous and 26% had R1 resections (p = 0.006); biliary
changes were due to open unresectability in 51% (p =
0.002); patients with liver lesions experienced a lesser
yield from laparoscopy, and a higher rate of "other" rea-
sons for intent change, including the identification of a
second intraoperative diagnosis and a complete response
after preoperative chemotherapy (p = 0.01); and stomach
cancers had a higher unresectability rate (42% of changes)
identified by laparoscopy, and a lower rate of benign dis-
ease proof (p = 0.01); finally, soft tissue resections dis-
played a higher rate of "other" intent changes, due to
unsuspected tumor origin or extent (p = 0.019).
Potential preoperative palliation goals were not achieved
in 15% of cases. Planned operations with palliative com-
ponents (n = 47) did not succeed in seven patients for the
following reasons: unresectable malignant disease (n = 4,
of which 3 were later palliated by endoscopic maneuvers),
no malignant disease process (n = 2, both with symptoms
relieved), and persisting early postoperative symptoms
despite an accomplished resection (n = 1). In five
instances without specific palliation needs stated preoper-
Preoperative versus postoperative assessment of operative intentFigur  1
Preoperative versus postoperative assessment of operative intent. Pall = palliative. Intent. Diagn = diagnostic intent. B9 Treatm 
= benign disease therapeutic intent. Comb = combined intent. The last bar represents the total number of patients with an 
intent change in any category, by definition a postoperative event.Page 5 of 9
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intraoperative findings for the following reasons: unre-
sectable pancreatic cancer where symptoms were strongly
suspected to develop (preemptive bypass, n = 2), cancer
recurrences detected intraoperatively and linked to preop-
erative symptoms (n = 2), and unresectable esophageal
cancer with gastrostomy and jejunostomy access to enable
chemoradiation (n = 1). Most palliative goals were created
for gastric cancer (n = 18, 38%), colon cancer (n = 8,
17%), pancreatic cancer (n = 5, 11%) and pelvic malig-
nancies (n = 5, 11%; p < 0.0001). Postoperative palliation
assignment were most common in the same diagnostic
groups (p < 0.0001).
Postoperative reassessment of stage assignment
Of 266 patients with preoperative (clinical) stage assign-
ment, 121 (45.5%) ultimately were classified into a differ-
ent pathohologic stage category postoperatively. Patients
undergoing a curative intent procedure were restaged
50.4% of the time. Among these, some significant devia-
Table 3: Postoperative curative treatment intent change and preoperative biopsy status (in %)






No preoperative biopsy obtained 34 0 17
Preoperative biopsy failed to demonstrate cancer 62 28 21
Positive preoperative biopsy 3 72 62
Totals (%) 100 100 100
p < 0.0001
Frequency of reasons for a postoperative change of the preoperative intentigur  2
Frequency of reasons for a postoperative change of the preoperative intent. dz = disease. dx = diagnosis. CR = complete 
response. R2 = R2 resection. R1 = R1 resection. b9 = benign.Page 6 of 9
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Compared to their respective controls, liver resections led
to stage reassignment in only 26.9% (p = 0.0001), while
biliary (71.4%, p = 0.018) and pancreatic resections
(58.7%, p = 0.04) did so more frequently. Other organ
sites were linked to stage reassignments in 77.8%
(esophageal), 60.4% (gastric), or 55.6% (colonic) of
cases, but differences to controls were not significant.
Discussion
The presented analysis reflects an attempt to specify oper-
ative indications for all surgical procedures performed in
a tertiary cancer center setting by a surgical oncologist
with a practice focus on gastrointestinal cancer. The
results show that under current practice standards, preop-
erative therapeutic intent still frequently differs from post-
operative assessments. Discrepancies appear to be disease
site specific, and relate to shortcomings in diagnosis or
therapy. However, situations of apparent changes of indi-
cation assessment cannot be equated with not indicated
or improperly performed operations. Only 7% of all
patients, or 25% of those with a postoperative intent
change would have benefited from no operative proce-
dure or from a different operation. Changes in indication
assessment, primarily observed in operations with an ini-
tial curative intent, much rather reflect the imprecision of
diagnostic and staging information which still accompa-
nies today's operative decision making, despite an obvi-
ous improvement in diagnostic imaging over the past
decade. The experience presented reflects findings and
challenges of a gastrointestinal oncology practice, which
includes some conditions that can be localized to an inter-
face between benign and malignant diseases, such as pan-
creatic masses or biliary strictures. Accordingly, disease-
specific reasons for intent changes are most likely to
emerge for diseases most prevalent in this practice,
namely pancreatic, hepatobiliary, and upper gastrointesti-
nal cancer, and benign conditions within the same organ
sites. Despite this, the overall results, irrespective of dis-
ease-specific implications, deserve further comment.
Patients presenting with a localized mass lesion, without
evidence for extraregional or unresectable disease, gener-
ally are candidates for surgical resection. In contrast to
nonoperative oncological therapy, a tissue diagnosis is
frequently not required in order to proceed, especially if
surrogate tests such as serum tumor marker levels are
abnormal. Irrespective of the presence of an invasive neo-
plasm or a precancerous or benign process, an operation
is indicated, as diagnostic clarification, cancer cure, or
therapeutic solution to a noncancerous process can all
hereby be achieved. Preoperative intents, therefore, may
well be reasonably combined, based on acceptable short-
comings of available information that is best clarified
through the operation itself and not through additional
expensive tests. In cases of symptoms caused by a malig-
Table 5: Multiple logistic regression of variables associated with the failure to perform a curative resection (confirmation of 
unresectability, or R1/2 resection)
Covariate p Value OR
Biliary case < 0.0001 5.83
Combined purpose preoperatively < 0.0001 3.60
No benign treatment purpose preoperatively 0.0002 19.67
Stomach case 0.0054 2.82
Pancreas case 0.0108 2.36
OR = odds ratio
Combined purpose preoperatively: multiple indications (such as cure, access, benign condition treatment) existed simultaneously
No benign treatment purpose preoperatively: a benign condition treatment indication (such as cholecystectomy for gallstones, incisional hernia 
mesh repair, etc.) did not exist aside from the curative indication
Table 4: Frequency rank of unresectability findings by organ resection sites, based on laparoscopy and open laparotomy results
Rank Unresectable by laparoscopy Unresectable by open laparotomy Unresectable (combined)
1 biliary 20% (4/20) biliary 15% (3/20) biliary 35% (7/20)
2 stomach 16% (8/51) retroperitoneal 13% (1/8) esophagus 22% (2/9)
3 esophagus 11% (1/9) esophagus 11% (1/9) stomach 20% (10/51)
4 small intestine 11% (1/9) colon 10% (1/10) pancreas 14% (15/110)
5 pancreas 5% (6/110) rectum 9% (1/11) retroperitoneal 13% (1/8)
6 liver 2% (1/49) pancreas 8% (9/110) small intestine 11% (1/9)
7 liver 6% (3/49) colon 10% (1/10)
8 stomach 4% (2/51) rectum 9% (1/11)
9 liver 8% (4/49)Page 7 of 9
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bined. It does not appear sensible to divide cases prior to
an operation into just either curative or palliative, as
attempted by McCahill et al., [17], since both curative and
palliative potential may coexist preoperatively in some
patients, as demonstrated before for gastric cancer [18]. It
is however important to stress that a noncurative proce-
dure does not automatically equal a palliative assignment.
Again, in a clinical gastric cancer series, 19% of gastrecto-
mies were considered noncurative, but only 48% of those
were apparently performed for palliative reasons; the
resulting survival was significantly shorter after palliative
resections than after noncurative, nonpalliative gastrecto-
mies [19]. This supports the strategy to delineate curative,
palliative, and other operative needs and apparent poten-
tial preoperatively, and balance operative options with
available nonoperative approaches such as endoscopic
palliative stenting. For cancers with curative potential,
combined preoperative indications apparently have
important implications. In this series, patients with com-
bined preoperative goals had a lesser likelihood for a suc-
cessful curative procedure, especially if no unrelated
benign condition was to be addressed operatively at the
same time. Although not entirely obvious, it is likely that
patients are offered additional components such as chole-
cystectomy or incisional hernia repair when less sympto-
matic, either due to lesser tumor burden, or because of a
better performance status. Combined intent categories
may thus also represent surrogates for other relevant out-
come predictors.
Unresectability (in 42 patients) and positive margin resec-
tions (in 23 individuals) have been the dominant reasons
for a failure to accomplish a potentially curative proce-
dure in cancer patients within this series. Modern imaging
has significantly improved the ability to predict resectabil-
ity. As example, 3D computed tomography has been
reported to accurately predict general resectability of pan-
creatic cancers in 79%, and of other periampullary cancers
in 98%; R0 resection was predicted in 73% and 86%,
respectively [20]. Diagnostic laparoscopy has greatly
reduced the frequency of unnecessary laparotomies in
patients with metastatic cancer. Biliary cancer, in this
series the leading diagnosis for failure to resect, allowed
for only a 31% resectability in a series of 100 patients; of
all unresectable patients, 51% were identified by laparos-
copy, but 49% only through an open procedure [21] The
primary challenge here would appear to be an improved
way to predict resectability of local, nonmetastatic dis-
ease.
The second reason for not achieving a curative outcome
was positive margin resection. For essentially all gastroin-
testinal adenocarcinomas R1/2 resections can be equated
with an exceedingly high risk of cancer recurrence, and
limited overall survival. Again, R0 rates are lowest for bil-
iary cancers; in a recent series, it was only 53%, and only
R0 resections led to prolonged survival [22]. For other dis-
eases such as gastric cancer, the outcomes after R0 resec-
tion depend on nodal disease burden, as distant
recurrence and death may take place prior to any sympto-
matic margin recurrence in patients with advanced stage
disease [23]. Even for malignancies other than adenocar-
cinomas, incomplete resection and positive margins have
been linked to poor survival, such as retroperitoneal
liposarcomas [24]. The primary challenge of this category
appears to be better margin prediction through improved
preoperative imaging, as well as preoperative treatment
strategies to reduce the risk for incomplete resection. In
this clinical series, intraoperative frozen section was liber-
ally utilized in situations where a wider resection of a con-
cerning margin area was feasible and would have allowed
a R0 procedure. Positive margins thus primarily reflect
either radial margins of specimens after committing to a
resection, for which wider dissection was not deemed safe
or sensible (e.g. the retroperitoneal soft tissue and supe-
rior mesenteric artery margin during pancreatoduodenec-
tomy), or margins accepted because of an advanced
disease burden (e.g. esophageal margin after gastrectomy
for N3 gastric cancer). As stated earlier, intraoperative fro-
zen section had not been utilized in mass lesions for
which a resection indication was given, irrespective of an
underlying malignant or benign process. The change in
"curative" intent in this category is therefore not suggested
to be improved by any other intraoperative means.
What then is the impact of the presented findings on this
practice in the future? Disease-specific preoperative
workup has been adjusted to include endoscopic ultra-
sonography routinely for those lesions that have been cor-
related with a high unresectability rate as defined through
open laparotomy, such as biliary cancers or rare hepatic
malignancies with a higher risk for extraregional nodal
involvement. Endoscopic ultrasound has also routinely
been applied to pancreatobiliary cystic lesions, to deline-
ate which cysts are to be resected based on defined imag-
ing criteria, and which are to be followed over time.
Diagnostic laparoscopy will be performed for those can-
cers with palliative indications, for which alternative pal-
liation means are to be preferentially chosen in case of
advanced peritoneal or visceral metastatic disease burden.
Borderline resectable cancers with curative intent, as
defined by endoscopic ultrasound, are to be routinely
considered for preoperative induction therapy, in order to
avoid positive margin resections. Finally, increasing use of
metabolic imaging, such as through positron emission
tomography, will reduce the number of patients with
advanced disease and the risk for extraregional metastases
undergoing curative intent operations in the future.Page 8 of 9
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The present study highlights some challenges in merely
assigning operative treatment goals preoperatively, and
achieving these goals based on postoperative review.
Obviously, such assessment only considers operative and
pathologic information, but not postoperative outcomes.
Unfortunately, truly successful postoperative curative or
palliative results are rather rare in these patients, even
when an operation itself could be considered to carry this
potential. Complications, recurrences, and failure to con-
trol symptoms or achieve a high level functional status are
all sad reminders that an assessment based on intraopera-
tive findings still remains rather imprecise and carries lim-
ited clinical predictive ability. Failure to achieve the
intended operative goal, however, can be a useful predic-
tor of poor outcomes, primarily the failure to cure a malig-
nant process. In conclusion, the formulation of precise
operative indications pre- and postoperatively is recom-
mended to optimize individual outcomes and avoid
unnecessary or ineffective procedures for gastrointestinal
cancer. Procedures with curative intent are not supporta-
ble unless a R0 resection can be achieved. Noncurative
indications should be justified based on the efficacy of
symptom control, and based on the lack of less invasive
alternatives.
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